Filgotinib: Completed Phase II enrollment

Galapagos completed enrollment of 175 patients with active CD and evidence of mucosal ulceration in the double-blind, placebo-controlled, European Phase II FITZROY trial to evaluate once-daily 100 and 200 mg oral GLPG0634 for 20 weeks. Galapagos expects to report 10-week primary endpoint data in December and 20-week data in 1Q16. ...